By Sam Boughedda Amgen (NASDAQ:AMGN) was reiterated at Neutral with a $208 per share price target by a Mizuho analyst on Monday, despite the stock's decline during the session...
By Senad Karaahmetovic Shares of Bristol-Myers Squibb (NYSE:BMY) are up about 7% in premarket Monday after the U.S. FDA approved Deucravacitinib, now known as Sotyktu, for the...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend.
Just as the dog days of summer have very little to do with dogs and everything to do with heat, so went the first week of August in the markets. The emphasis was not on the dogs,...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
|Average||249.81 (+8.23% Upside)|
|No. of Analysts||28|